# US 12,594,024 B2 · Method for predicting survival of non small cell lung cancer patients with brain metastasis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,024 B2
- Document ID: US12594024B2
- Status: Granted
- Kind: B2
- Application number: 18/620,652
- Filed: 2024-03-28
- Published: 2024-12-19
- Granted: 2026-04-07
- Earliest claimed: 2023-06-19
- Assignees: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Applicants: The Catholic University of Korea Industry-Academic Cooperation Foundation
- Inventors: Seung Ho Yang; Young Il Kim; Hyun Ho Kim
- Web page: https://patentgrep.com/patent/US12594024B2

## CPC

- A61B 5/4519: {Muscles (measuring muscular strength A61B5/224; using electromyography [EMG] A61B5/389)}
- A61B 5/0042: {for the brain}
- A61B 5/055: involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
- A61B 5/0803: {Recording apparatus specially adapted therefor}
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

The present invention relates to a method for predicting survival of non-small cell lung cancer patients with brain metastasis. More specifically, it proposes a method that is useful for predicting the survival of the patients by comparing TMTrg of the patients with cut off value for predicting long term survival.

## Claims

### Claim 1

A method of treating a patient diagnosed with a non-small cell lung cancer with brain metastasis, the method comprising:
(a) calculating a temporal muscle thickness reduction gradient (TMTrg) from the patient as calculated by:
TMTrg=(Final temporal muscle thickness (TMT)−Initial TMT)/Follow-up period,
wherein,
the Final TMT is a TMT measured at a survival prediction point and is measured in millimeters (mm);
the Initial TMT is a TMT measured at initial diagnosis of the patients' brain metastasis and measured in mm; and
the Follow-up period is an interval between Initial TMT measurement time point and Final TMT measurement time point and measured in months; and
(b) treating the patient with surgery, chemotherapy, radiation, or administering a therapeutic agent when the calculated TMTrg is −0.185 or more and less than 0.

### Claim 2 (depends on 1)

The method of claim 1, further comprising treating the patient with palliation of the non-small cell lung cancer with brain metastasis when the patient's calculated TMTrg is not −0.185 or more and less than 0.

### Claim 3 (depends on 1)

The method of claim 1, wherein calculating the Final TMT and the Initial TMT is performed with magnetic resonance imaging data.